Articles

The US Food and Drug Administration (FDA) approved enzalutamide (Xtandi; Medivation, Inc., Astellas Pharma US, Inc.) for the treatment of patients with metastatic castration-resistant prostate cancer who had previously received docetaxel. Read More ›

Abiraterone acetate is a novel antiandrogen agent that has recently received an expanded indication for treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Read More ›

The US Food and Drug Administration (FDA) approved pertuzumab (Perjeta; Genentech) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Read More ›

The US Food and Drug Administration (FDA) approved everolimus (Afinitor; Novartis Pharmaceuticals Corporation) for the treatment of postmenopausal women with advanced hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. Read More ›

The US Food and Drug Administration (FDA) approved carfilzomib (Kyprolis; Onyx Pharmaceuticals, Inc.) for the treatment of patients with multiple myeloma who have received at least 2 prior therapies and who have demonstrated disease progression. Read More ›

Chronic myeloid leukemia (CML) is a clonal proliferative disorder of the hematopoietic cells of myeloid lineage1-3 driven by a reciprocal translocation between chromosomes 9 and 22, resulting in the so-called Philadelphia (Ph) chromosome. Read More ›

Results from a study by the gastroenterologists at Arizona Digestive Health in Phoenix, AZ, that were presented at Digestive Disease Week show that patient use of a smartphone app significantly improves colonoscopy preparation. Read More ›

In a comprehensive investigation involving decades of published studies, Mayo Clinic researchers have determined that patients with inflammatory bowel disease (IBD) are at a 37% greater risk for melanoma. Read More ›

A new prostate cancer treatment drug, Xofigo (radium Ra 223 dichloride), has been approved by the FDA for use in men with symptomatic late-stage castration-resistant prostate cancer that has metastasized only to bones. Read More ›

Researchers from University of Michigan Health System (UMHS) compared central venous catheters (CVCs) with peripherally inserted central catheters (PICCs) and discovered that the risk of dangerous blood clots doubled with the use of PICCs, especially among ICU and cancer patients. Read More ›